A phase II trial of BST-204 in patients with cancer induced muscle loss (cancer cachexia)

Trial Profile

A phase II trial of BST-204 in patients with cancer induced muscle loss (cancer cachexia)

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs BST-204 (Primary)
  • Indications Cachexia
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
    • 27 Dec 2017 New trial record
    • 20 Dec 2017 According to a Green Cross media release, the company expects to initiate this study prior to the end of the first quarter 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top